Additional Permitted Disclosures. In addition to the disclosures permitted under Section 8.2.1 above, DICERNA and KHK each agrees that the Receiving Party may disclose the Confidential Information of the Disclosing Party (including the terms of this Agreement) (a) on a need-to-know basis to such Disclosing Party’s legal and financial advisors; (b) as reasonably necessary in connection with an actual or potential (i) permitted sublicense of such Receiving Party’s rights hereunder, (ii) Third Party collaborators or licensees, or debt or equity financing of such Receiving Party, subject in each case to written obligations of confidentiality substantially similar to those of the Parties hereunder, or (iii) merger or sale of all or substantially all of the Receiving Party’s business unit to which this Agreement relates or in the event of the merger or consolidation or similar change of control involving such Receiving Party; (c) to any Third Party that is or may be engaged by the Receiving Party to perform services in connection with the Research Collaboration; and (d) for any other purpose with the Disclosing Party’s written consent, not to be unreasonably withheld, conditioned or delayed.
Appears in 3 contracts
Samples: Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc), Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc), Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc)